Market Overview

UPDATE: Credit Suisse Downgrades Amgen to Neutral; Upgrade Catalysts Have Passed

Share:
Related AMGN
Amgen, Celgene Buck Short Interest Trend In Biotech Stocks
Chardan: Sell Regeneron After Sanofi Drops Patent Infringement Bombshell
Amgen Valuation Now Excludes Potential Repatha Revenue (Seeking Alpha)

Credit Suisse downgraded Amgen (NASDAQ: AMGN) from Outperform to Neutral and lowered the price target to $90.00.

Credit Suisse commented, "The principal reason for our downgrade is that the 3 key elements of our July 2012 report entitled "Upgrading to Outperform = Agency cost + operational gearing + defensive macro call" have been realized, in our veiw [sic] (Please refer to our note,"Upgrading to Outperform = Agency cost + Operational gearing + Defensive macro call", published on July 25). We believe investors are likely looking for fundamental (i.e., pipeline and strategy) improvements/triggers in 2013. We have made no changes to our P&L estimates."

Amgen closed at $82.07 on Friday.

Latest Ratings for AMGN

DateFirmActionFromTo
Feb 2016Argus ResearchMaintainsBuy
Feb 2016Leerink SwannInitiates Coverage onMarket Perform
Jan 2016Credit SuisseMaintainsOutperform

View More Analyst Ratings for AMGN
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Downgrades Intraday Update Analyst Ratings

 

Related Articles (AMGN)

View Comments and Join the Discussion!

Get Benzinga's Newsletters